# Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Shilpa Prabhakar, Roberta L. Beauchamp, Pike See Cheah, Akiko Yoshinaga, Edwina Abou Haidar, Sevda Lule, Gayathri Mani, Katia Maalouf, Anat Stemmer-Rachamimov, David H. Jung, D. Bradley Welling, Marco Giovannini, Scott R. Plotkin, Casey A. Maguire, Vijaya Ramesh, and Xandra O. Breakefield
Correspondence: breakefield@hms.harvard.edu, ramesh@helix.mgh.harvard.edu
https://doi.org/10.1016/j.omtm.2024.101262

(Molecular Therapy: Methods & Clinical Development *26*, 169–180; September 2022)

In the originally published version of this article, the data for Figure S11 were mistakenly transcribed inaccurately. The authors have gone back to the original data stored in the bioluminescence machine and obtained the correct data, which are now plotted as the correct Figure S11. There are no changes in the conclusion. The comparison of figures is shown below.

Time point (in wks)	AAV1-Null	AAV1-Null	AAV1-FLAG-Merlin
2	130000	221000	9280
3	152000	249000	22600
4	584000	478000	19000
5	1700000	1460000	8700
6	1.52e+007	764000	20300
7	1.13e+007	243000	25300
8	2.77e+007	340000	14900
9	5.92e+007	296000	13100
10	5.68e+007	1830000	300000
11	1.77e+007	1120000	11700
12	5.56e+007	1500000	33600
13	3.82e+007	179000	15100
14	6.61e+007	42700	76500
15	1.97e+008	485000	-55500

Figure S11. Growth of human schwannoma tumors injected with AAV1-FLAG-merlin and AAV1-null vectors (corrected)